Enovis (ENOV) Could Be 23% Undervalued After Return To Profit And Guidance Reset

Enovis (ENOV) just packed several moving parts into a single week. The medical technology company reported third quarter results, tightened full year revenue guidance, and unveiled a fresh US$200 million share repurchase program.

The recent guidance tweak and fresh buyback authorization come after a sharp swing in sentiment. Enovis has a 30 day share price return of 45.55%, while the 1 year total shareholder return is down 10.46% and the 5 year total shareholder return is down 68.48%. This points to short term momentum building against a long record of weaker investor outcomes.

Scan how Enovis stacks up against other potential rebound stories by checking a curated set of 20 high quality undiscovered gems in similar recovery phases.

Enovis has just flipped back into profit while the share price has sprinted ahead in a month. Do you lean into this reset now, or wait for the next pullback before running the numbers?

Most Popular Narrative: 23% Undervalued

Enovis is trading at $27.64 compared with a fair value of $36.08 in the analyst consensus Narrative on Simply Wall St. This builds on analyst price targets along with their revenue and earnings forecasts using an 8.96% discount rate.

Improving free cash flow conversion, with a target of greater than 25% in 2026, at least 50% and at least US$100 million of free cash generation in 2027, and around 70% conversion by 2029, provides Enovis with more flexibility to reduce leverage and return capital, which can support earnings per share through lower interest expense and a smaller share count.

See why 4 investors see Enovis as 23% undervalued.

Result: Fair Value of $36.08 (UNDERVALUED)

Still, the Enovis story can break if integration of Lima and the planned eCential Robotics deal keeps margins under pressure, or if the robotics rollout drags longer than analysts expect.

Find out about the key risks to this Enovis narrative.

Next Steps

Mixed signals around Enovis can make the story feel noisy, so move quickly to your own verdict by weighing both the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Enovis?

If Enovis has sparked fresh questions about where to put your next dollar to work, do not stop here. Broader opportunity often sits just outside your current watchlist.

• Hunt for mispriced quality by scanning a curated group of companies screened as 32 high quality undervalued stocks that may offer a more attractive entry point.
• Prioritise resilience and sleep better at night by focusing on businesses in our 29 resilient stocks with low risk scores that pair steadier risk profiles with cleaner fundamentals.
• Target balance sheet strength so future shocks hurt less by filtering for companies in the list of solid balance sheet and fundamentals (23 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com